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A B S T R A C T   
Copper oxide nanoparticles (CuO NPs) have previously been shown to cause dose-dependent pulmonary toxicity 
following inhalation. Here, CuO NPs (10 nm), coated with polyethylenimine (PEI) or ascorbate (ASC) resulting in 
positively or negatively charged NPs, respectively, were evaluated. Rats were exposed nose-only to similar 
exposure dose levels of ASC or PEI coated CuO NPs for 5 consecutive days. On day 6 and day 27 post-exposure, 
pulmonary toxicity markers in bronchoalveolar lavage fluid (BALF), lung histopathology and genome-wide 
transcriptomic changes in lungs, were assessed. BALF analyses showed a dose-dependent pulmonary inflam-
mation and cell damage, which was supported by the lung histopathological findings of hypertrophy/hyperplasia 
of bronchiolar and alveolar epithelium, interstitial and alveolar inflammation, and paracortical histiocytosis in 
mediastinal lymph nodes for both types of CuO NPs. Transcriptomics analysis showed that pathways related to 
inflammation and cell proliferation were significantly activated. Additionally, we found evidence for the dys-
regulation of drug metabolism-related genes, especially in rats exposed to ASC-coated CuO NPs. Overall, no 
differences in the type of toxic effects and potency between the two surface coatings could be established, except 
with respect to the (regional) dose that initiates bronchiolar and alveolar hypertrophy. This disproves our hy-
pothesis that differences in surface coatings affect the pulmonary toxicity of CuO NPs.   
1. Introduction 
Copper oxide nanoparticles (CuO NPs) are widely studied due to 
their considerable toxicity towards human cells and following pulmo-
nary exposure in rodents, which is more severe than would be expected 
from the dissolved metal alone (Karlsson et al., 2008; Lanone et al., 
2009; Wang et al., 2012; Wongrakpanich et al., 2016). For example, 
CuCl2 (used as an ion control) elicited significantly less cytotoxicity 
when compared to the CuO NPs in a murine macrophage cell line 
(Líbalová et al., 2018). 
CuO NPs have been commonly used as preservatives and disinfec-
tants with a broad range of applications, from the treatment of wood to 
paint additives and electronics, which may result in significant occu-
pational hazards resulting from inhalation (Brenner et al., 2016; 
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Pantano et al., 2018). We and others have described the pulmonary 
toxicity of airborne CuO NPs including damage to bronchoalveolar 
epithelial cells accompanied by inflammation (Cho et al., 2010; Gosens 
et al., 2016; Ilves et al., 2019). Moreover, our recent investigations 
revealed changes at the level of gene expression that are compatible 
with aggressive hyperplasia and a potential risk of lung pre-neoplasia, 
corroborated by the (transient) upregulation of oncoproteins (Costa 
et al., 2018). 
According to the safety by molecular design concept, the NPs surface 
modification with suitable coatings is a strategy often used to potentially 
reduce their toxicity (Yan et al., 2019). NP surface coating molecules can 
play a role in the control of NP reactivity by influencing the direct 
interaction between the coating molecules and the biological target of 
by affecting colloidal stability and thereby determining their fate in 
body. Furthermore, coatings can interact with various toxicants, acting 
as scavenging or complexing agents of ions or ROS, thereby influencing 
their bioavailability (Sanità et al., 2020). 
Previously, we have prepared and investigated a panel of CuO NPs 
with different surface modifications using murine RAW264.7 
macrophage-like cells as a model. Both ascorbate (ASC) and poly-
ethylenimine (PEI) surface modifications, prepared in a phosphate 
buffer solution, by colloidal self-assembling, resulted in a more well- 
dispersed NPs in water with a significant decrease of the average hy-
drodynamic diameter size in comparison with the uncoated (pristine) 
material. The negative ζ potential of CuO NPs was enhanced by the 
negative ASC coating, as derived by the presence of surface surrounding 
phosphate ions. The PEI-coating yielded a positive ζ potential in water, 
but not in DMEM (Ortelli et al., 2017, for a detailed description of the 
NPs in various biological media). We noted that positively charged 
polyethylenimine (PEI) modified NPs were the most cytotoxic while 
negatively charged ascorbate (ASC) coated NPs where the least cytotoxic 
(Líbalová et al., 2018). Furthermore, CuO-ASC yielded a lower degree of 
superoxide production in cells as compared to pristine CuO NPs. 
Understanding the molecular mechanisms of nanoparticle toxicity 
will inform safer and sustainable nanotechnology approaches . How-
ever, as pointed out by Buchman et al. (2019), the “redesign strategies 
will need to be chosen based on the major mode of toxicity”. Shi et al. 
(2012) applied mercaptocarboxylic acids with different carbon chain 
lengths for stabilizing CuO NPs and noted that NPs with longer chain 
ligands had surfaces that were better protected from oxidation and a 
corresponding lower ROS generating capacity compared to particles 
with shorter chain ligands. Sun et al. (2015) addressed the safe-by- 
design concept with respect to fumed silica and found that titanium 
and aluminum doping was useful in terms of mitigating the cytotoxicity 
and pro-inflammatory responses of silica NPs in THP-1 cells. In a sub-
sequent study, the authors synthesized a combinatorial library in which 
CuO was doped with 1–10% Fe and performed hazard screening of 
doped versus non-doped particles in cell lines and zebrafish embryos 
(Naatz et al., 2017). The authors could show that the Cu+/Cu2+ and 
Fe2+/Fe3+ redox species played a major role in the dissolution process 
and, hence, in determining the toxicity of the NPs. 
In general, positively charged NPs have been suggested to bind to cell 
surfaces and internalised by cells more efficiently when compared to 
negatively charged NPs (Zhao et al., 2011). For instance, PEI coating of 
mesoporous silica NPs enhanced uptake in macrophages (Clemens et al., 
2012). Taken together, these findings suggest that surface coating of 
CuO NPs could serve as a means of achieving safer materials, according 
to the safe-by-design (SbD) approach, and this led us to hypothesize that 
CuO-ASC NPs could be less toxic than CuO-PEI NPs. To evaluate this in 
an in vivo model, we exposed rats to different doses of CuO-ASC or CuO- 
PEI and assessed lung response parameters including BALF analysis, 
histopathology and genome-wide gene expression changes. We 
compared the toxic effects of the two surface modified CuO NPs using a 
previously described short-term inhalation protocol (Gosens et al., 
2016). 
2. Materials and methods 
2.1. Nanomaterials 
CuO NPs were obtained from a commercial source (PlasmaChem, 
GmbH, Berlin, Germany). For details on the characteristics of the pris-
tine CuO NPs, see Gosens et al. (2016). Modified CuO stock suspensions 
were then prepared as described previously (Ortelli et al., 2017). In 
short, 10 g/L of Cu (1 wt%) in phosphate buffered saline (PBS) was 
mixed with 10 wt% of either PEI or ASC (Sigma-Aldrich) with respect to 
the total amount of copper oxide to obtain surface modified CuO NPs. 
CuO-PEI and CuO-ASC suspensions were filtered using a centrifugal 
filter unit (Amicon Ultra-15, 10 kDa, Millipore) to remove unabsorbed 
capping agent. The obtained samples (wet powder, after the elimination 
of solvent though ultrafiltration) were dried in the oven at T = 100 ◦C. 
After drying, thermogravimetric analysis was carried out to determine 
the real amount of capping agent. To this end, suspensions were heated 
at a rate of 10 ◦C/min up to T = 1000 ◦C in air flux by thermo- 
microbalance (STA 449C, Netzsch-Gerätebau GmbH, Selb/Bavaria, 
Germany). The estimated adsorbed amount of citrate or ascorbate 
resulted 1,3 and 5,8 wt%, respectively, as referred to the total amount of 
CuO. 
CuO PEI and CuO ASC NP stability characterization was assessed in 
lung simulant fluids Gamble’s solution and artificial lysosomal fluid 
(ALF) in a similar fashion as previously described for CuO NPs (Gosens 
et al., 2016). In short, CuO NP dispersions were prepared in simulant 
fluids at a concentration of 100 mg/L. Samples were taken after 1 and 
24 h at 37 ◦C and passed through centrifugal filter units. The Cu content 
was determined by inductively coupled plasma optical emission spec-
trometry (ICP-OES). 
2.2. Animals 
Specific pathogen free 6 week old male Wistar rats (RjHan:WI) were 
obtained from Janvier, France. At arrival, the animals were weighed, 
randomly allocated and were acclimated for 1–2 weeks before starting 
the experiment. The study design, including five days of exposure and 
22 days of recovery are outlined in Suppl. Fig. S1. Before the start of the 
exposure, the average weight (±SD) of the rats was 240 ± 20 g with the 
weight evenly distributed among the exposure groups. Animals were 
weighed after exposure before dissection and once a week during the 
recovery period. Food and water were provided ad libitum, except during 
the exposure in nose-only tubes. Experiments were performed at the 
National Institute for Public Health and the Environment in Bilthoven, 
Netherlands, in accordance with the Principles of Laboratory Animal 
Care and with the guidelines approved by the Dutch Ethical Committee 
in full accordance with European legislation. 
2.3. Aerosol generation 
CuO-PEI and CuO-ASC aerosols were generated from stock suspen-
sions (10 mg/mL, 1% wt) that were diluted in ultrapure water (to 2 mg/ 
mL, 0.2% wt), using a Schlick compressed air spray-nozzle (Düsen- 
SchlicK, GmbH, Untersiemau/Coburg Germany). The characteristics of 
the stock solutions are described in Líbalová et al. (2018). The suspen-
sions were continuously stirred on a magnetic stirrer and metered to the 
spray-nozzle with an adjustable peristaltic pump. The primary aerosol 
was diluted with pressurized air, heated, and dried in a mixing chamber 
and further diluted with moisturized air to a total of 38 L per minute 
(22 ◦C, 55%RH) and split equally over the two exposure towers. Particle 
number counts and size distributions were measured daily during the 
experimental period using a condensation particle counter CPC 3022A 
and a scanning mobility particle sizer SMPS model 3936 in combination 
with the OPS 3330 (all from TSI, St. Paul, MN). The mass concentration 
was measured with a TEOM series 1400a (Rupprecht & Patashnick, 
Albany, NY). A time weighted average exposure concentration was 
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calculated from a continuous aerosol collection on 47 mm Teflon filters 
using a Mettler MC/ME-5 micro-balance. A time weighted mass median 
aerodynamic diameter MMAD was determined using an eight-stage 
(+after filter) cascade impactor MOI Model No. 110 (MSP Corp, Min-
neapolis, MN). A 1-min sample was taken every half hour. A schematic 
representation of the aerosol generation in given in Suppl. Fig. S2 and a 
schematic representation of the MOI sampling to determine the MMAD 
is provided in Suppl. Fig. S3. 
2.4. Aerosol exposure 
Animals were exposed nose-only to a single generated exposure 
concentration of CuO-PEI or CuO-ASC, and to clean air as a control for 5 
consecutive days. By placing the animals in the exposure set-up for 
various durations (7 min, 20 min, 1 h and 3 h), different dose levels of 
exposure were obtained (Suppl, Table S1). Animals exposed for dura-
tions shorter than 3 h to the nanomaterial aerosol, were exposed to clean 
air for the remainder of the 3-h period. This concentration times time (C 
x T) protocol follows Gosens et al. (2014), according to OECD Guideline 
403. A 3-h concentration equivalent is derived by multiplying the 
duration of exposure by the exposure concentration (designated as dose 
C x T) and scaling it to the highest exposure duration of 3 h, see Suppl. 
Fig. S1 for the dose groups dedicated for toxicological examination (n =
5 per group) and organ burden analysis (n = 4 per group), respectively. 
The animals autopsied at Day 1 after the 5 days repeated exposure were 
designated as “main” group and the animals autopsied at Day 27–28 
were designated as “recovery” group. Based on our in vitro experiments 
(Líbalová et al., 2018), toxicity was expected to be lower following 
exposure to CuO-ASC. To increase the chance of finding comparable and 
complete dose-response curves for both CuO-PEI and CuO-ASC, animals 
were exposed to a slightly higher concentration of CuO-ASC. 
2.5. Lung dissection 
Animals were weighed at 1 and 22 days after the final exposure day, 
and were killed by exsanguinations from the abdominal aorta under 
anesthesia with a mixture of ketamine (75–100 mg/kg) and xylazine (10 
mg/kg) administered intramuscularly. Then, the abdomen and thorax 
were opened, and blood was withdrawn from the abdominal aorta. A 
cannula was placed in the trachea and the diaphragm was opened. The 
left lung was clipped, while the right lung was flushed once using 26.7 
mL/kg body weight of saline. The flush consisted of 3 up and down 
movements in order to collect bronchoalveolar lavage fluid (BALF). 
2.6. Bronchoalveolar lavage fluid analyses 
Bronchoalveolar lavage fluid (BALF) was obtained as described 
above. Only BALF data with a recovery >60% of the flushing solution 
was included in the analysis. The reason for a lower recovery rate was 
accidental damage to the lung before or during flushing, which occurred 
only in 1 out of 60 animals. The BALF was centrifuged at 400 ×g at 4 ◦C 
for 10 min. Lactate dehydrogenase (LDH), alkaline phosphatase (ALP), 
N-acetylglucosaminidase (NAG), γ-glutamyltransferase (GGT), and total 
protein content was measured in the supernatant using an auto-analyzer 
(LX20-Pro, Beckman-Coulter, Woerden, Netherlands) according to the 
manufacturer’s instructions. The cell pellet was suspended in 1 mL of 
PBS for total cell counts (Coulter counter). Specimens of 400 cells/glass 
slide were then produced by cytospin preparation. 
2.7. Hematology 
Blood samples were collected as described above using an EDTA 
containing system. Hematological parameters were determined in an 
Advia 120 Hematology Analyzer (Siemens Health Care, Berlin, Ger-
many). The blood parameters determined were: hemoglobin, packed cell 
volume, red blood cell count, reticulocytes, total white blood cell count, 
differential white blood cell count, prothrombin time, thrombocyte 
count, mean corpuscular volume, mean corpuscular hemoglobin, and 
mean corpuscular hemoglobin concentration. No exposure related 
changes in hematology parameters were found (data not shown). 
2.8. Organ burden analysis 
Organs were weighed and prepared as detailed in Gosens et al. 
(2016), with modifications. In brief, freeze-dried lung, liver, brain, 
kidney, spleen and heart were acid digested using a microwave (ETHOS 
1600, Milestone) assisted method with the following programme: ramp 
to 250 W for 1 min, 0 W for 1 min, 250 W for 5 min, 400 W for 3 min, 
600 W for 3 min. After heating, the sample solutions were diluted and 
analysed by inductively coupled plasma mass spectrometry (ICP-MS) 
equipped with single channel Universal Cell (sp-ICP-MS NexION 
350XXD, Perkin Elmer). Potential contamination from the laboratory 
was controlled by adding at least one procedural blank during each 
digestion session. The limit of detection (LOD) and the limit of quanti-
fication (LOQ) were calculated for each sample set as the average of 
blanks + 3 standard deviations (SD) and as the average of blanks + 10 
SDs, respectively. In order to verify the accuracy and repeatability of the 
method, 6 aliquots of the standard reference material (SRM) NIST 1577c 
(bovine liver) were analysed every 10 samples. The average Cu con-
centration (±SD) detected in the SRM was 277 ± 5 mg/kg1, in agree-
ment with the reference value (267 ± 6 mg/kg1). With respect to the 
certified value, the recovery of Cu ranged from 90 to 101%. Cu con-
centrations reported for the different organs correspond to three ICP-MS 
readings and are expressed on a dry weight basis. 
2.9. Histopathology 
The weight of organs (left lung, left brain hemisphere, kidneys, liver 
and spleen) of 5 animals of the main study group and recovery groups 
(Suppl. Fig. S1) was determined prior to preservation in a neutral 
aqueous phosphate-buffered 4% solution of formaldehyde (10% solu-
tion of formalin). Tissues were embedded in paraffin wax, sectioned at 5 
μm and stained with hematoxylin and eosin for histological examina-
tion. The left lungs were infused and prepared for histopathological 
examination (3 levels) as previously described (Gosens et al., 2016). Left 
lungs were examined for all doses of the main group, clean air control 
and in the recovery group. Mediastinal lymph nodes and nasal cavities 
(4 levels) were examined for all doses of the main group, the clean air 
controls and highest dose of the recovery group. Liver, spleen, kidneys, 
and brain were examined from all main and recovery animals in clean 
air controls and at the highest dose of the CuO NPs. 
2.10. Microarray analysis 
Total RNA was isolated from individual rat lungs (n = 5 per exper-
imental condition) with the AllPrep DNA/RNA Mini kit (Qiagen, Hilden, 
Germany), following the manufacturer’s instructions. Quantification 
and primary quality assessment were done with a NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific). The RNA integrity num-
ber (RIN) for each RNA sample was then determined with an Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and RIN 
values were consistently 7. Labelled cDNAs and cRNAs were synthesized 
from 200 ng of total RNA per lung sample using the Linear Amplification 
Kit or the Universal Rat Reference RNA (both from Agilent). T7 RNA 
polymerase-transcribed cRNAs were subsequently labelled with 
Cyanine-5 while UMRR was labelled with Cyanine-3. An equimolar 
amount of UMRR cRNAs was mixed with each experimental cRNA and 
hybridized to SurePrint G3 Rat 8 × 60 K microarrays (Agilent). Micro-
array slides were washed and scanned using a G250B apparatus, with 
data being retrieved with the software Feature Extraction 10.7.3 (all 
from Agilent). Further details can be found in Halappanavar et al. 
(2015). 
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2.11. Bioinformatics 
Microarray data were analysed using R 3.5.x (Ihaka and Gentleman, 
1996). Further details can be found in Halappanavar et al. (2015) and 
Costa et al. (2018). In brief, following data normalization through 
locally weighted scatterplot smoothing regression modelling from a 
randomised block design, the significance of differentially expressed 
genes (DEGs) was determined by the Fs statistic with residual shuffling 
(Cui et al., 2005). The respective p-values were corrected for false dis-
covery rates (FDR), as described by Benjamini and Hochberg (1995). 
Fold change ratios (FC) relatively to controls were estimated as least- 
squared means between replicates. A gene was considered differen-
tially expressed if |FC| > 2 (up- or downregulated) and FDR-corrected p 
< 0.05. Downstream analyses, including Venn diagrams, hierarchical 
clustering, functional annotation and gene ontology and gene enrich-
ment were conducted using packages limma, edgeR, biomaRt and 
KEGGprofile for R, as described previously (Costa et al., 2018). Pathway 
analysis with causal networks (Krämer et al., 2014) was performed using 
the Ingenuity Pathway Analysis (IPA) software (application version 
220217, content version 16542223, licensed by Ingenuity Systems, 
Redwood City, CA). Results were filtered by p < 0.05 and activation |Z|- 
score > 2. 
2.12. ELISA 
Lung tissue (100 mg) from each of three rats per clean air control and 
the highest exposure for the main and recovery group were dissected, 
rinsed with PBS and lysed in T-PER™ tissue protein extraction reagent 
(Thermo Scientific) in the presence of 1× Halt™ Protease and Phos-
phatase Inhibitor Cocktail (Thermo Scientific). Tissue homogenization 
was accomplished by taking advantage of the Qiagen TissueLyser II 
Sample Disruption/Homogenizer System using 3 mm tungsten carbide 
beads (Qiagen). Following centrifugation (10,000 ×g, 10 min), protein 
supernatant concentrations were determined by Pierce™ BCA Protein 
Assay kit (Thermo Fisher Scientific). All samples were then diluted to 
0.67 μg/mL in 1× ELISA sample diluent buffer (Millipore). Enzyme- 
linked immunosorbent assay (ELISA) analysis was performed in tripli-
cates for each sample using the rat Lcn2/NGAL ELISA kit (Sigma), ac-
cording to the manufacturer’s instructions. The data are reported as ng 
of Lcn2 per mg of lung tissue, based on the standard curve for Lcn2 
provided with the kit. 
2.13. Statistical analysis 
Copper levels in the different organs were analysed by 2-way ANOVA 
using Sidak’s multiple comparison test. Clinical pathology parameters 
were log transformed and analysed by 2-way ANOVA using Tukey’s 
multiple comparison test. Benchmark doses (BMD) and their one-sided 
lower and upper 95%-confidence limits (BMDL and BMDU, respec-
tively) were estimated using PROAST (Gosens et al., 2015; idem, 2016). 
A benchmark response (BMR) of5% change was chosen for organ and 
body weight endpoints and a BMR of 100% for cell counts and BALF 
clinical chemistry. Differential cell counts were analysed as clustered 
quantal data, i.e., as a number within a sample of 400 cells. No defaults 
are available for this type of response, therefore the BMR was set to a 
20% extra fraction based on expert judgment. For the (ordinal) histo-
pathology data, the BMR was set to 50% risk (EC50), indicating the 
concentration at which the average animal develops the considered 
lesion of a predefined severity (Slob, 1999; Slob et al., 2014). Potency 
differences due to coating with PEI or ASC were analysed using the BMD 
approach including a covariate for coating (Slob, 2002). BMD plots are 
provided in the Supplementary information, Figs. S4–S17. 
3. Results 
3.1. Characterization of aerosols of surface modified CuO NPs 
Although the CuO NPs have a primary particle size of 10 nm (mode, 
9.2–14 nm – first and third quartile respectively) based on TEM analysis 
(Gosens et al., 2016), the CuO-PEI aerosol has a MMAD of 1.27 μm and 
geometric standard deviation (GSD) of 2.01 and the CuO-ASC aerosol 
has a MMAD of 1.17 μm and GSD 2.14. It is a well-known phenomenon 
for NPs to aggregate/agglomerate when dispersed in air, due to their 
dynamic motion and high surface energy, especially in the aereosolisa-
tion process employed here using a spray nozzle (Grassian et al., 2007, 
Eslamian and Ashgriz, 2007). 
Using the computational Multiple-Path Particle Dosimetry (MPPD) 
model (software version 3.04, www.arra.com/mppd) (Anjilvel and 
Asgharian, 1995), the pulmonary deposition fraction for CuO-PEI was 
estimated to be 0.045 and the tracheobronchiolar fraction 0.096 for a 
17.5 mg/m3 aerosol with a density of 6.3 g/cm3 (Suppl. Fig. S18). After 
exposure for 3 h per day for 5 consecutive days using a rat inhalation 
rate of 0.01 m3/h, the pulmonary plus tracheobronchiolar load for CuO- 
PEI was estimated to be 0.37 mg. Given that both aerosols have very 
comparable MMAD and GSD, the pulmonary deposition fraction for 
CuO-ASC was estimated to be very similar to CuO-PEI, namely 0.046 and 
the tracheobronchiolar fraction 0.091. This results in a total lung load 
for CuO-ASC of 0.43 mg after exposure to 20.9 mg/m3 for 3 h per day for 
5 days. The prepared CuO-PEI and CuO-ASC stock suspensions (10 mg/ 
mL) for aerosol generation were checked for endotoxin content. The 
CuO-PEI suspension contained less than the lowest detectable level of 3 
IU/mL (0.3 IU/mg NPs). In addition, for the aerosol generation, the 
stock suspensions were diluted 5 times resulting in less than 0.06 IU/mg 
endotoxin content. To estimate the possible endotoxin level per rat we 
assumed that the endotoxin is associated with the CuO NPs. In the top 
dose group, rats are exposed for 5 days, 3 h per day to 17 mg/m3 aerosol 
generated from the 2 mg/mL suspension. At day 6, after some clearance 
has already occurred, this resulted in a lung burden of 8.4 μg copper. The 
total amount of endotoxin per rat is estimated to be 0.0005 IU. For CuO- 
ASC, with a measured endotoxin level in the suspension of <4.5 IU/mL 
and a lung burden of 8.7 μg copper, this results in very low levels (0.09 
IU/mg and 0.0008 IU per rat). 
The static dissolution of CuO PEI and CuO ASC NPs was assessed in 
lung simulant fluid, i.e., Gamble’s solution and artificial lung lining fluid 
(ALF) and the ratio Cu2+ ion versus CuO NPs was determined by ICP-OES 
at 1 and 24 h (Table 1). As a reference 10 mL of a 100 mg/L CuO 
dispersion was used. Both CuO PEI and CuO ASC NPs showed a strong 
dependence on pH and the presence of amino acids complexing media. 
Table 1 
Dissolution of CuO nanoparticles in Gamble’s solution and artificial lysosomal 

























































Total concentration of CuO, calculated as: Cu (conc)/MW (Cu) * MW (CuO). 
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3.2. Evaluation of pulmonary impact of CuO NPs 
The short-term inhalation study protocol was applied as described 
previously (Gosens et al., 2016), with a few modifications. The study 
design is presented in Suppl. Fig. S1. In brief, toxicological parameters 
were assessed one day after the final exposure (on day 6) and after a 
recovery period of 22 days (i.e., study day 27, recovery group). Each 
group consisted of 5 animals. Groups for organ burden analysis consisted 
of 4 animals. 
3.3. Histopathological evaluation of lungs, lymph nodes and nasal cavity 
Exposure to CuO-PEI or CuO-ASC did not lead to mortality, or 
changes in the behaviour of the animals during the exposure and re-
covery period. No treatment-related histopathological changes were 
visible in the liver, spleen, kidneys, and brain (data not shown). 
Exposure-related histopathological findings after treatment with both 
CuO-PEI and CuO-ASC were noted in the lung of all treatment groups 
(Suppl. Tables S2 and S3 resp.), in the mediastinal lymph nodes (Suppl. 
Tables S4 and S5, respectively), and in the nasal cavities (Suppl. 
Tables S6 and S7, respectively). A minimal to slight increased incidence 
in alveolar macrophages was observed in the lower dose groups (at 
0.6–6.0 mg/m3 for CuO-PEI and at 0.8–2.3 mg/m3 for CuO-ASC) most 
likely representing the phagocytic response of the alveolar macrophages 
to particulate material. At higher doses, this process progressed into an 
alveolar and/or interstitial inflammatory response consisting of abun-
dant granulocytes and/or macrophages which was dose-dependent (at 
0.6–17.3 mg/m3 CuO-PEI and at 2.3–21.8 mg/m3 CuO-ASC). The in-
flammatory response was accompanied by the presence of cell debris in 
the alveoli. In addition, at all doses of CuO-PEI and at 7.5–21.8 mg/m3 
CuO-ASC alveolar and/or bronchiolar hypertrophy/hyperplasia was 
observed (Suppl. Tables S2 and S3, Fig. 1A–D). After a recovery period of 
22 days, a minimal (CuO-ASC) to slight (CuO-PEI) increase in alveolar 
macrophages was still observed and minimal bronchiolar hypertrophy/ 
Fig. 1. Histopathology of the lung and nose 
following short-term inhalation exposure. (A) clean 
air exposure for 5 consecutive days, day 1–5. Detail of 
air containing alveoli (*) and septa (#). (B) CuO-PEI, 
day 6 (exposure dose 17.3 mg/m3 for 5 consecutive 
days, day 1–5). (C) CuO-ASC, day 6 (exposure dose 
21.8 mg/m3 for 5 consecutive days, day 1–5). Note 
presence of alveolar and interstitial inflammation 
with cellular debris in alveoli in B and C. (D) CuO- 
PEI, day 6 (exposure dose 17.3 mg/m3 for 5 consec-
utive days, day 1–5. Detail of bronchiolar hypertro-
phy (#) in the lung. (E) Nasal epithelium after clean 
air exposure day 6 (clean air exposure for 5 consec-
utive days, day 1–5). Note presence of normal nasal 
epithelium (#) including goblet cells, cartilage in 
nasal septum (*) and nasal bone (¶). (F) Nasal cavity 
after clean air exposure. Note regular arrangement of 
nuclei of the cells in the epithelial cell layer. Note 
normal nasal epithelium (#). (G) Nasal cavity after 
CuO-PEI, day 6 (exposure dose 17.3 mg/m3 for 5 
consecutive days, day 1–5). Note slight disorganiza-
tion of the cell nuclei in the epithelium (#). Refer to 
the supplement for a quantification of the histopath-
ological findings.   
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hyperplasia was noted in two animals. This is indicative of ongoing 
clearance of CuO NPs by alveolar macrophages accompanied by resto-
ration of the normal lung architecture. The alveolar and interstitial 
inflammation was resolved, while bronchiolar and alveolar epithelium 
recovered (Suppl. Tables S2 and S3). 
Furthermore, a dose-dependent increased incidence and severity of 
histiocytosis was observed in the paracortical region of the mediastinal 
lymph nodes after both treatments (Suppl. Figs. S19B–C). Note that 
some histiocytosis is also observed in clean air controls (Fig. S19A). The 
potencies of both types of NPs in causing histiocytosis when assessed 
using the BMD approach, is equal (the confidence intervals BMDU- 
BMDL for PEI and ASC overlap, 2.1–5.6 mg/m3). After the CuO-free 
period of 22 days, for both coatings no histiocytosis occurred, suggest-
ing full recovery (Suppl. Tables S4 and S5). 
In a few animals (1 animal at 1.8 and 6.0 mg/m3 CuO-PEI, and 4 
animals at 21.8 mg/m3 CuO-ASC of which 1 animal after recovery) 
disorganization of the olfactory epithelium was observed (Fig. 1E–G). 
This disorganization represented atrophy, the presence of pycnotic 
nuclei and unstructured epithelial cell layers, or a combination of these 
features. Based on the relatively low severity of the changes and the fact 
that some disorganization of the epithelium remained only in 1 animal 
in the recovery group, while effects generally had resolved, this finding 
seems of minimal toxicological significance (Suppl. Tables S6 and S7). 
The remainder of the recorded findings in liver, spleen and kidneys were 
within the range of background histopathology in rats of this strain and 
age, and not considered to be treatment-related. No hematological ab-
normalities were noted. 
3.4. Benchmark dose modelling of the lung impact of CuO aerosols 
Exposure to both types of modified CuO NPs induced a dose- 
dependent increase in several BALF markers such as the total cell 
number (Fig. 2A–B) and LDH, indicative of cell damage (Fig. 2C–D). 
We also observed an increase in the number of macrophages and 
neutrophils, as well as in the presence of total protein, ALP, NAG, and 
GGT (data not shown). The nature of the toxicological response in rats 
after exposure to CuO-PEI and CuO-ASC was found to be similar with the 
same markers affected. Using the BMD approach, the potency difference 
between the two aerosols was analysed (Suppl. Table S8). The only 
difference in response to CuO-ASC and CuO-PEI is that exposure to CuO- 
PEI led to bronchiolar hypertrophy at a lower dose compared to CuO- 
ASC, while CuO-ASC led to alveolar hypertrophy at a lower dose 
compared to CuO-PEI (Fig. 3). This difference in alveolar versus bron-
chiolar hypertrophy could be due to slight differences in lung deposition 
between positively and negatively charged aerosols. The deposition 
according to MPPD modelling did not result in a difference in the 
deposited fraction in alveoli versus the bronchial area (see above). 
However, the MPPD model does not take differences in particle charge 
into account while this could influence the deposition. 
Fig. 2. BALF analysis reveals inflammation and cellular damage (n = 5 per group). (A) Total cell concentration after exposure to CuO-ASC, (B) total cell concen-
tration after exposure to CuO-PEI, (C) LDH after exposure to CuO-ASC, and (D) LDH after exposure to CuO-PEI at 1 day after exposure (day 6) and after a recovery 
period of 22 days (i.e., day 27). 
Fig. 3. Summary of benchmark dose (BMD) confidence intervals for lung 
toxicity markers after exposure to CuO-PEI and CuO-ASC aerosols expressed as 
3-h exposure equivalents. When the statistical analysis showed that there is no 
difference in the potency between the aerosols, a single BMD confidence in-
terval is derived and plotted for ASC and PEI (ASC and PEI on the right side of 
the figure).Potency differences were observed only for bronchiolar and alveolar 
hypertrophy, based on histopathological findings. This is indicated with a 
separate BMD confidence interval for ASC and PEI. 
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3.5. Organ burden analysis at day 6 and day 27 after exposure 
No exposure related increases above background Cu levels were 
observed at day 6 or day 27 following exposure to either CuO-PEI or 
CuO-ASC (Suppl. Fig. 20) in organs other than in the lung, similarly to 
what has been found for the pristine CuO NPs (Gosens et al., 2016). In 
the lung, the increasing exposure (as 3-h exposure equivalents) resulted 
in an increase in lung burden at day 6. After subtracting the background 
Cu levels, exposure to the top dose CuO-PEI (3-h exposure equivalent 
17.5 mg/m3) resulted in a lung burden of 32.6 μg copper per gram dried 
lung weight at day 6. Based on the actual average dry lungs weight of 
260 mg, this resulted in a total lung burden of 8.4 μg copper. A similar 
calculation results in a lung burden of 32.4 μg copper per gram dried 
lung weight after exposure to the top dose of CuO ASC (3-h exposure 
equivalent 20.9 mg/m3) and a total lung burden of 8.7 μg copper (actual 
average dried lung weight 270 mg). Within the 21-day recovery period, 
Cu was completely cleared from the lung (Fig. 4A–B). The lung burden 
following a 3-h exposure to CuO-PEI and CuO-ASC was compared to the 
6-h exposure to CuO pristine by transforming the 3-h exposure to a 6-h 
exposure following the C × T concept and expressing it on a log to log 
scale. Both exposure to CuO-PEI and CuO-ASC resulted in a similar lung 
burden compared to CuO pristine (Fig. 4C). A true quantitative com-
parison is not possible, since the rat strain and age/body weight of the 
rats were different between the studies for PEI/ASC (the present study) 
and pristine CuO NPs (Gosens et al., 2016). Unfortunately, an infection 
problem at the breeder of the strain used in the previous study with 
pristine CuO NPs prevented us from using the same rat strain in the 
present study. 
3.6. Microarray analysis of gene expression changes in rat lungs 
Next, we performed transcriptomics analyses of total lung tissues of 
exposed and control rats. We identified a total of 654 significant DEGs, 
almost entirely pertaining to rats sampled after exposure (Suppl. 
Fig. S21A), i.e., at day 6, comparatively to rats enduring exposure plus 
recovery (at day 27) (Suppl. Fig. S21B), which is in accordance with our 
previous work on rats exposed to unmodified CuO NPs (Costa et al., 
2018). However, in contrast with the preceding study, the number of 
juxtaposed DEGs between treatments is much higher and there is a more 
even distribution of up- and downregulated genes. The highest fold 
change (FC ≈ 70) pertains to lcn2 encoding lipocalin 2, a protein 
involved in the sequestration of iron, in animals exposed to CuO-ACS 
(high dose) (Suppl. Table S9). This gene was also overexpressed in the 
remaining treatments following exposure (but not recovery) (FC ranging 
from about 11–16). This was followed by defb3 encoding the anti- 
microbial peptide beta-defensin 3 in rats exposed to CuO-PEI (low 
dose). Interestingly, the D-box binding PAR bZIP transcription factor 
(dpb), which regulates the expression of some drug-metabolizing cyto-
chrome P450 (CYP) enzymes was consistently found to be the most 
upregulated gene in CuO-ASC exposed animals (FC ≈ 20) (Suppl. 
Table S9). Downregulation was strongest for gp2 encoding glycoprotein 
2 (a pathogen-binding protein involved in innate immune responses) in 
CuO-PEI exposed animals (low dose, after recovery) (FC ≈ − 6). This 
was followed by the serpin B10 encoding gene (serpinb10) in CuO-PEI 
exposed animals (high dose) and the CYP encoding gene cyp26b1 in 
CuO-ASC exposed animals (low dose), both immediately after exposure 
(day 6) (FC ≈ − 5) (Suppl. Table S9). To provide validation of these data 
at the protein level, we focused on the top-most affected gene lcn2, 
encoding lipocalin 2 (Lcn2). To this end, lung tissue samples from rats 
exposed to the highest dose of CuO-PEI or CuO-ASC at day 6 and rats 
following exposure plus recovery (at day 27) versus control were sub-
jected to analysis by ELISA. As shown in Suppl. Fig. S20, Lcn2 levels 
were markedly elevated at day 6 both for CuO-PEI and CuO-ASC 
exposed groups and were normalized at day 27. 
Hierarchical cluster analysis (Fig. 5) of all DEGs and treatments 
showed a consistent differentiation between exposure and recovery, 
while differences between the two surface modifications were scant, 
regardless of dose (see dendrogram at the top of the heatmap). Gene 
ontology associated pathways with two major clusters of DEGs that 
included most of the probes (Benjamini-adjusted p ≈ 0) were identified 
(Fig. 5). The first (upper) cluster includes genes that affect steroid 
metabolism (4 genes) and basal metabolic pathways (16 genes) as the 
top-most statistically significant. The second cluster includes major 
immune response pathways, the top-most being IL-17 signaling (11 
Fig. 4. Organ burden analysis (n = 4 per group). Lung Cu burden (in μg/g organ dry weight) was assessed 1 day after the last exposure (day 6) and after a recovery 
period of 22 days (day 27) in control animals and in animals exposed to 1.8 mg/m3 and 17.5 mg/m3 CuO-PEI (A) or 2.3 mg/m3 and 20.9 mg/m3 CuO-ASC (B), for 5 
consecutive days. (C) Lung burden comparison between studies using pristine CuO (Gosens et al., 2016) and modified CuO (the present study). * indicates significant 
differences compared to control (2-way ANOVA with Sidak’s multiple comparisons test, p < 0.05). 
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Fig. 5. Transcriptomics analysis of rat lungs following 
exposure to CuO NPs. Heatmap comprising all 654 
differentially expressed genes (DEGs), normalized by 
row (i.e., by gene). Hierarchical clustering of genes 
(dendrogram to the left) and experimental treatments 
(upper dendrogram) was done using Euclidean dis-
tances and complete linkage analysis. The two major 
clusters of DEGs are denoted (1) and (2). The upper 
cluster includes genes that affect steroid metabolism 
(adj. p-value: 7.867333e-06) and metabolic pathways 
(adj. p-value: 2.241742e-03), while the lower cluster 
includes immune related pathways, such as IL-17 
signaling (adj. p-value: 1.449865e-06) and cytokine- 
cytokine receptor interactions (adj. p-value: 
2.094660e-06).   
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genes) and cytokine-cytokine receptor interaction pathways (17 genes). 
Furthermore, pathway analyses using IPA yielded strong activation 
(z-score > 2) of canonical pathways related to inflammation and cell 
cycle in samples collected at day 6, i.e., immediately after exposure, with 
no evident differences between CuO-PEI and CuO-ASC (Fig. 6A). The 
most significantly deactivated pathway, in all 6-day rats (albeit highest 
in the PEI group) was cell cycle: G2/M DNA damage checkpoint regu-
lation (re-activated after recovery), which is in agreement with the 
activation of cell cycle- and mitogenesis-related pathways. The segre-
gation between exposure and recovery treatments, as well as the overall 
similarity between CuO-PEI and CuO-ASC, was even more obvious when 
comparing disease and function pathways. 
Here we found pathways pertaining to innate immunity and cell 
proliferation (including lung cancer cells, forming a distinct cluster of 
pathways) consistently activated after exposure and deactivated after 
recovery. Five out of sixteen pathways were related to granulocyte 
(especially neutrophil) mobilization, while three pathways were related 
to cancer cell proliferation. Notably, immune response and cell prolif-
eration networks were linked by the upregulation of several common 
genes as illustrated in Fig. 7. Among these are the genes encoding 
epithelial cell transforming sequence 2 (ect2) and the C–C motif che-
mokine ligand 2 (ccl2) (Suppl. Table S10). 
Fig. 6. Hierarchical clustering of molecular pathways as determined by Ingenuity Pathway Analysis (IPA) of the transcriptomics data combining all experimental 
conditions (exposure and recovery). (A) Cluster analysis heatmap for ‘canonical pathways’. Clustering of pathways (left dendrogram) and treatments (upper 
dendrogram) was done with Euclidean distances and complete linkage computed from activation scores. (B) Cluster analysis heatmap for ‘diseases and functions’. 
Clustering of pathways (left dendrogram) and treatments (upper dendrogram) was obtained as above. 
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4. Discussion 
The present study aimed at comparing the in vivo effects of exposure 
through inhalation to the most and least cytotoxic surface-modified CuO 
NPs (CuO-PEI and CuO-ASC, respectively), according to our previous in 
vitro study using a macrophage-like cell line (Líbalová et al., 2018). We 
determined BALF inflammatory and cell damage markers, conventional 
histopathological endpoints and assessed gene expression changes by 
genome-wide microarray analysis. In brief, CuO-PEI and CuO-ASC dis-
played the same effects in terms of the type of toxicity endpoints that are 
affected following short-term inhalation exposure in a rat model. This, 
therefore, disproves our hypothesis that differences in surface coatings 
resulting in a positive or negative surface charge respectively, affects the 
pulmonary toxicity of CuO NPs. 
We noted that the lung burden of Cu per gram dried lung weight at 
day 6 was very similar for both CuO-PEI and CuO-ASC, and following a 
21-day recovery period, Cu was completely cleared from the lungs. 
Furthermore, our detailed histopathological examinations revealed 
exposure-related changes in the lungs of all treatment groups after 
exposure to both CuO-ASC and CuO-PEI. The alveolar and interstitial 
inflammation was resolved after a 21-day recovery period (i.e., at day 27 
of the study). No treatment-related histopathological changes were 
visible in the liver, spleen, kidneys, or brain. The response to CuO-PEI 
and CuO-ASC was found to be similar with respect to BALF analysis, 
which indicated a dose-dependent increase in the total cell number and 
LDH (a marker of plasma membrane disintegration). The very low levels 
of endotoxins detected on the NPs are unlikely to have contributed to 
these effects. 
By applying the statistical method of the BMD approach, we could 
make a fair comparison of the toxic effects on the entire exposure con-
centration range and assess potency differences between the two types 
of surface modified CuO NPs. BALF total cell number, differential cell 
counts and cell damage markers, absolute wet lung weights and the 
histopathology results were analysed in this fashion. The only difference 
in the pulmonary response was noted in the histopathology assessment. 
Exposure to CuO-PEI led to bronchiolar hypertrophy at a lower 
(benchmark dose) compared to CuO-ASC, while CuO-ASC led to alveolar 
hypertrophy at a lower dose compared to CuO-PEI. This may have been a 
consequence of the slight difference in the dose distribution between 
these two lung regions due to the electrostatic forces. As stated before, 
PEI coated CuO NPs had a positive ζ potential in water, while ASC coated 
NPs had a negative ζ potential. The aerosol was generated from a stock 
suspension in water. This, however, did not affect the overall dose in the 
lung, which explains why the less region specific BALF analyses did not 
show any difference between groups of rats exposed to CuO-ASC or CuO- 
PEI. Overall, the gene expression analysis corroborated these findings. 
Hence, CuO-PEI and CuO-ASC were found to elicit changes in pathways 
related to inflammation and cell proliferation, and these gene expression 
changes were largely restored to control levels following the 21-day 
recovery period. 
Fig. 7. Network analysis. The figure depicts the network associations between the two ‘diseases and functions’ pathways related to cell proliferation and immune 
responses (refer to main text). The probes corresponding to the two most significantly activated pathways in the lungs of animals exposed to the high dose of CuO-PEI 
(day 6) are shown. Note that the genes encoding lipocalin 2 (lcn2) and C–C motif chemokine ligand 2 (ccl2) are among those that connect the two networks in 
question; both are upregulated. 
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The microarray results obtained herein are concordant with our 
findings in an earlier study in which rats were exposed to pristine CuO 
NPs (Costa et al., 2018). Thus, molecular pathways related to inflam-
mation and cell proliferation were significantly activated during expo-
sure and largely returned to control levels during recovery. However, 
the present study also revealed that CuO-PEI triggered the deactivation 
of DNA damage checkpoint related genes, which is a risk factor for the 
onset of neoplasia (Calonge and O’Connell, 2008). Considering that Cu 
is a known genotoxicant and is even suspected to be a mutagen (Prá 
et al., 2008), our study suggests that pulmonary exposure to CuO NPs 
could potentiate the risk of developing neoplastic disease. 
Indeed, in a recent, comprehensive study, Rossner et al. (2020) 
employed next generation sequencing protocols and determined gene 
expression changes in the lungs of mice exposed to inhalation of CuO 
NPs (8 × 105 NPs/m3) for up to 3 months. Notably, at three months of 
exposure, the authors observed dysregulation of several genes poten-
tially implicated in carcinogenesis. In the present study, we found evi-
dence for the dysregulation of drug metabolism-related genes, especially 
in animals exposed to CuO-ASC, which may be interpreted as an attempt 
by the cells to eliminate the capping agent. It is worth noting that while 
ascorbate is an important physiological antioxidant it can also exert 
prooxidant effects in the presence of free transition metal catalysts (Frei 
et al., 1989). Thus, capping agents are not necessarily innocuous, and 
the toxicity of NPs may result from an interplay between particles and 
surface coatings, as shown previously (Líbalová et al., 2018). 
The present findings confirmed that the genes encoding CCL2 and 
ECT2 are significantly elevated in response to CuO NPs, in line with 
previous work (Costa et al., 2018). Furthermore, we found that among 
the 654 significant DEGs, the gene encoding lipocalin 2 displayed the 
greatest FC (almost 70-fold upregulation in rats exposed to CuO-ACS). 
These findings were validated by ELISA analysis of homogenized lung 
tissue samples from the high-dose group. Notably, lcn2 was also over-
expressed in rats exposed to unmodified CuO NPs in our previous study, 
but FCs were lower (≈19) (Costa et al., 2018). Lipocalin 2, also known as 
oncogene 24p3 or neutrophil gelatinase-associated lipocalin (NGAL), is 
an iron-binding protein that serves to complement the transferrin system 
(Kaplan, 2002). While LCN2/NGAL was originally identified as a 
component of neutrophil granules, it is also expressed in macrophages 
and in epithelial cells of the respiratory and gastrointestinal tracts. 
Recent studies suggested that LCN2 promotes bacterial clearance by 
macrophages, thereby suppressing inflammation (Toyonaga et al., 
2016). We studied whole lung tissue here, yet it is relevant to ask 
whether lcn2 upregulation occurs in macrophages, neutrophils, and/or 
epithelial cells in exposed animals. Kodali et al. (2013) suggested, based 
on transcriptional profiling, that common mechanisms for the dysre-
gulation of innate immunity exist by virtue of shared recognition path-
ways between certain NPs and pathogenic bacteria. 
Our previous work showed that CuO NPs, if dispersed in amino acid 
enriched media, tend to dissolve rapidly, even at high pH (the pH of 
DMEM is around 8), despite surface coating with PEI and ASC (Baldis-
serri and Costa, 2016; Líbalová et al., 2018). This is due to the known 
copper complexation ability of amino acids present in biological media 
that alter the dissolution equilibrium leading to an increase of the dis-
solved fraction (Borsook and Thimann, 1932; Gale and Winkler, 1977; 
Garnier and Tosi, 1975). Furthermore, pristine (non-modified) CuO NPs 
triggered the upregulation of mt1a and mt2a in the lungs of rats (Costa 
et al., 2018). Strauch et al. (2017) studied the cytotoxicity of nano- and 
micro-sized CuO NPs as compared to CuCl2 in human bronchial 
epithelial BEAS-2B cells and human lung adenocarcinoma A549 cells 
coupled with gene expression analysis and found a strong induction of 
the metallothionein (MT) genes, MT1X and MT2A. Hanagata et al. 
(2011) also noted upregulation of a host of MT genes in A549 cells 
exposed to CuO NPs. Similar upregulation of MT genes was presented in 
a recent transcriptomics report by Boyadzhiev et al. (2021), where 
mouse lung epithelial cells from MutaMouse were exposed to varying 
doses of CuO NPs, CuO MPs and CuCl2 for different periods of time. We 
showed that ZnO NPs elicit the upregulation of several MT genes in 
primary human monocyte-derived macrophages (Tuomela et al., 2013). 
In the present study, the most significantly overexpressed MT was mt1a, 
attaining FC = 2.83 in animals exposed to a high dose of CuO-ASC (and 
FC = 2.79 for the low dose treatment), whereas CuO-PEI reached FC =
2.28 and 2.15 (low and high dose, respectively). The expression of MTs 
returned to control levels after recovery (day 27). Overall, the induction 
of MT genes seems to serve as a common cellular response to metallic 
nanoparticles that readily dissolve. 
Our recent transcriptomics studies of rat lungs following pulmonary 
exposure to pristine CuO NPs failed to demonstrate significant pertur-
bations of pathways related to oxidative stress (Costa et al., 2018). 
Similarly, in the present study, oxidative stress genes or pathways were 
seemingly not affected. However, in vitro, the pathway perturbation 
following exposure to CuO NPs is shown to exhibit an incremental 
transition involving cellular stress (heat shock genes) and defense 
mechanism pathways at low dose and early post-exposure time points to 
oxidative stress, autophagy and early DNA damage pathways at mod-
erate doses and, DNA damage and cytotoxicity pathways at high dose/ 
late post-exposure time points (Boyadzhiev et al., 2021. Also, in vivo, the 
post-exposure time points at which the sampling is conducted plays an 
important role, which may explain why oxidative stress associated 
pathways were not observed in the present study. Additionally, in vivo, 
tissue anti-oxidative capacity may protect from mounting oxidative 
stress. Thus, even though oxidative stress is assumed to be important, its 
role in CuO NP-induced toxicity in vivo remains uncertain. Interestingly, 
Saporito-Magriñá et al. (2018) have recently provided evidence that 
while the cellular antioxidant glutathione (GSH) protects cells from Cu- 
mediated cytotoxicity this was independent of its reactive thiol group. 
The authors could show that cell death is driven by the interaction of 
cuprous ions with proteins which impairs protein folding and promotes 
protein aggregation. Consequently, cells reacted to Cu by mounting a 
heat shock response leading ultimately to cell death (Saporito-Magriñá 
et al., 2018). Indeed, in a recent proteomics-based study, we observed 
that CuO NPs triggered the upregulation of proteins involved in heat 
shock responses in the human monocytic leukemia cell line THP-1 
(Tarasova et al., 2017). Thus, a take-home message from these studies 
is that while transcriptomics-based approaches are exquisitely sensitive, 
protein expression changes are also important (Costa and Fadeel, 2016). 
Our comparative analysis of activation of the molecular pathways 
related to inflammation and cell proliferation showed few differences 
between CuO-ASC and CuO-PEI at low or high doses, which indicates a 
more significant impact of the NPs themselves, even though CuO-ASC 
were shown to be less cytotoxic than CuO-PEI when tested on mouse 
macrophages in vitro (Líbalová et al., 2018). Thus, one should exercise 
caution when attempting to extrapolate from in vitro assays (often based 
on a single cell type) to the in vivo situation where an interplay between 
different lung epithelial cells and immune cells take place. Nevertheless, 
the key factor which determines the outcome of CuO NP exposure is 
likely the fact that the NPs rapidly dissolve in the acidic environment of 
the lysosomal compartment of macrophages (Gosens et al., 2016; Zhang 
et al., 2018). Capping agents that prevent NP dissolution may mitigate 
their biological effects (Tuomela et al., 2013), but in the case of CuO- 
ASC and CuO-PEI, our studies show that both undergo dissolution in 
cell culture media (Ortelli et al., 2017; Líbalová et al., 2018). In the 
mouse macrophage assay (Líbalová et al., 2018), ASC and PEI coatings 
only modestly affected Cu dissolution, suggesting that the in vitro cyto-
toxicity is modulated by the interaction between coating agent and 
copper bioavailability and not copper levels insides the cells alone. 
Our results indicate that effects of the initial surface characteristics of 
the CuO PEI (positively charged) and ASC (negatively charged) NPs, are 
mitigated by the environment encountered in the lung after the inha-
lation exposure resulting in similar adversity. A similar observation has 
been made when comparing TiO2 NPs with an endogenous negative 
charge versus surface modified TiO2 NPs with a positive charge (Wallin 
et al., 2017). In our study, the toxicity did not seem to be surface charge/ 
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chemistry dependent. Looking to descriptors that potentially affect fate 
and toxicity in in vivo models such as the colloidal stability (degree of 
agglomeration) and metal ions release, we did not find significant dif-
ferences between the two samples. In particular, the static dissolution 
data of both CuO PEI and CUO ASC NPs in lung simulant fluids showed a 
strong dependence from pH and the presence of amino acids complexing 
media. CuO-PEI NP dissolution needs more time to reach equilibrium, 
but after 24 h the ratio Cu2+/CuO is the same (75%). In terms of NPs 
dispersability in water, CuO-ASC resulted the best dispersed sample 
(DLS-size ≈ 100 nm for CuO-ASC and ≈250 nm for CuO-PEI), if 
compared with naked CuO (DLS-size ≈ 1000 nm), but this effect is lost 
once NPs are aerosolised and agglomerate inside the aereosolisation 
chamber. Based on the results of the present study, a possible suggestion 
to overcome limits of the proposed safe-by-design strategy, is to explore 
inorganic coatings (e.g., silica) that can limit the bioavailability of 
leached ions, acting as an entrapping matrix (Gardini et al., 2018). 
5. Conclusions 
Using a short-term inhalation protocol (Gosens et al., 2016; Costa 
et al., 2018), we found that the functionalized CuO NPs by ASC and PEI 
elicited a dose-dependent pulmonary inflammation and cell damage. 
Furthermore, transcriptomics analysis showed that pathways related to 
inflammation and cell proliferation were significantly activated. A small 
difference was found in CuO-PEI leading to bronchiolar hypertrophy at a 
lower (benchmark) dose compared to CuO-ASC, while CuO-ASC led to 
alveolar hypertrophy at a lower dose compared to CuO-PEI. This could 
be due to a difference in the dose deposition in these lung regions as a 
result of a differences in electric charges. Overall, no differences in the 
type of toxic effects or toxic potency in the lung could be established 
between the two surface coatings. This disproves our hypothesis that 
CuO-ASC NPs would be less toxic than CuO-PEI NPs per unit mass. 
Notwithstanding, our study has shown good concordance between 
conventional toxicity methods and the more sensitive microarray-based 
transcriptomics analyses of lung tissues. 
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